Stifel Nicolaus analyst Paul Matteis maintained a Hold rating on Alkermes (ALKS – Research Report) yesterday and set a price target of $28.00. The company’s shares closed yesterday at $23.86.
Matteis covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Alkermes, and BioMarin Pharmaceutical. According to TipRanks, Matteis has an average return of 6.7% and a 45.57% success rate on recommended stocks.
Currently, the analyst consensus on Alkermes is a Moderate Buy with an average price target of $34.00, a 42.50% upside from current levels. In a report released yesterday, H.C. Wainwright also reiterated a Hold rating on the stock with a $35.00 price target.
The company has a one-year high of $32.88 and a one-year low of $20.46. Currently, Alkermes has an average volume of 2.06M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alkermes (ALKS) Company Description:
Alkermes Plc is a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include Aristada, which is used for the treatment of schizophrenia in adults; and Vivitrol, which is an injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.
